For any synthetic AT developed, it is important to know which biomolecule the agent is designed to protect, by which mechanism (scavenging RS, preventing RS formation, increasing endogenous defense mechanisms, and/or supporting oxidative damage repair), whether it can generate RS, and if there are any adverse effects associated with RS suppression
doi: 10.1038/nm.3009 44 CoskunTSloopKWLoghinCAlsina-FernandezJUrvaSBokvistKBet al
[DOI] [PMC free article] [PubMed] [Google Scholar] 81.Shapiro S.B., Yin H., Yu O.H.Y., Rej S., Suissa S., Azoulay L
Three patients (50%) had sensorimotor disturbances, 2 patients (33%) had bowel and bladder dysfunction, and 2 patients (33%) had palpable masses
Clinical trials demonstrate that GLP-1 medications produce weight reductions of 15 to 22 percent of body weight, substantially outperforming topiramate and other older weight loss agents